Rhenman & Partners Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Rhenman & Partners Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Buy	33,250 +5,250	+19%	+$291K	0.19%	90
2026 Q1	$1.63M	Sell	28,000 -111,000	-80%	-$5.11M	0.2%	82
2025 Q4	$6.23M	Buy	139,000 +58,000	+72%	+$2.44M	0.58%	58
2025 Q3	$3.25M	Buy	81,000 +46,000	+131%	+$1.62M	0.36%	72
2025 Q2	$1.1M	Hold	35,000	–	–	0.14%	87
2025 Q1	$1.17M	Hold	35,000	–	–	0.14%	85
2024 Q4	$1.37M	Hold	35,000	–	–	0.14%	85
2024 Q3	$1.38M	Hold	35,000	–	–	0.11%	91
2024 Q2	$1.36M	Buy	+35,000	New	+$1.4M	0.13%	83

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rhenman & Partners Asset Management's XENE Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its Xenon Pharmaceuticals (XENE) stake by 19% in Q2 2026, buying an estimated $291K and bringing the position to 33,250 shares worth $2.01M. The position accounts for 0.19% of the portfolio, ranked #90.

Rhenman & Partners Asset Management first reported a position in XENE in Q2 2024 and has held it in 9 quarters since. The position peaked at $6.23M in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Rhenman & Partners Asset Management held 33,250 shares of Xenon Pharmaceuticals worth $2.01M as of Q2 2026.
Rhenman & Partners Asset Management bought 5,250 Xenon Pharmaceuticals shares in Q2 2026, an estimated $291K.
Xenon Pharmaceuticals made up 0.19% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #90 holding.
Rhenman & Partners Asset Management first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Rhenman & Partners Asset Management's Xenon Pharmaceuticals position peaked at $6.23M in Q4 2025.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.